{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:32:46Z","timestamp":1649093566663},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/inf.0b013e31829f2694","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T10:55:45Z","timestamp":1376736945000},"page":"e53-e59","source":"Crossref","is-referenced-by-count":3,"title":["Consequences of Prior Use of Full-dose Ritonavir as Single Protease Inhibitor as Part of Combination Antiretroviral Regimens on the Future Therapy Choices in HIV-1\u2013Infected Children"],"prefix":"10.1097","volume":"33","author":[{"given":"Ute D.","family":"Feucht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Rossouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Van Dyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-18-20210202","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"South Africa Resistance Cohort Study Team. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R4-18-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/QAD.0b013e3282f2be1d","article-title":"Pharmacokinetics, safety and efficacy of lopinavirritonavir in infants less than 6 month of age: 24 week results.","volume":"22","author":"Chadwick","year":"2008","journal-title":"AIDS"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.","volume":"47","author":"Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-18-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0036-46652005000100001","article-title":"Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).","volume":"47","author":"Machado","year":"2005","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181af5a00","article-title":"Emergence of drug resistance in HIV-1 subtype C infected children failing the South African National Antiretroviral roll-out.","volume":"28","author":"Wallis","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R8-18-20210202","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/QCO.0b013e3283298f1f","article-title":"Management of paediatric HIV-1 resistance.","volume":"22","author":"Gupta","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/651455","article-title":"Antiretroviral therapy in children with tuberculosis: progress toward defining the issues.","volume":"201","author":"Cotton","year":"2010","journal-title":"J Infect Dis"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/INF.0b013e3181af829d","article-title":"Protease inhibitor resistance in South African children with virologic failure.","volume":"28","author":"van Zyl","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2011.0284","article-title":"Southern Africa Treatment And Resistance Network (SATuRN). Primary drug resistance in South Africa: data from 10 years of surveys.","volume":"28","author":"Manasa","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R14-18-20210202","first-page":"212","article-title":"Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.","volume":"10","author":"Martinez-Cajas","year":"2008","journal-title":"AIDS Rev"},{"key":"R15-18-20210202","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/01.inf.0000177281.93658.df","article-title":"PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.","volume":"24","author":"Chadwick","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R16-18-20210202","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/651454","article-title":"Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.","volume":"201","author":"Reitz","year":"2010","journal-title":"J Infect Dis"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/aid.2010.0205","article-title":"Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.","volume":"27","author":"Taylor","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R19-18-20210202","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2223\/JPED.1877","article-title":"Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.","volume":"85","author":"Almeida","year":"2009","journal-title":"J Pediatr (Rio J)"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.","volume":"47","author":"Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R21-18-20210202","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection.","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"R22-18-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1054-3589(07)56009-6","article-title":"Viral drug resistance and fitness.","volume":"56","author":"Quinones-Mateu","year":"2008","journal-title":"Adv Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e31829f2694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:11Z","timestamp":1620954731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201402000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31829f2694","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}